{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:15:25Z","timestamp":1778260525490,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109996","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T03:37:53Z","timestamp":1678678673000},"page":"109996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Novel evidence of Thymosin \u03b11 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8445-512X","authenticated-orcid":false,"given":"Daniela","family":"Ricci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena Paola","family":"Etna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-4545","authenticated-orcid":false,"given":"Martina","family":"Severa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-5492","authenticated-orcid":false,"given":"Fabiana","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Teresa","family":"Palamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana Marina","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.109996_b0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0010","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De Biasi","year":"2020","journal-title":"Nat. Commun."},{"issue":"10229","key":"10.1016\/j.intimp.2023.109996_b0015","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2023.109996_b0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7861\/clinmed.2022-0080","article-title":"A practical update on the management of patients with COVID-19","volume":"22","author":"Mehta","year":"2022","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.intimp.2023.109996_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100058","article-title":"Host directed therapies: COVID-19 and beyond","volume":"2","author":"Tripathi","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109996_b0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1196\/annals.1415.039","article-title":"Thymosin alpha1: a historical overview","volume":"1112","author":"Garaci","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"sup1","key":"10.1016\/j.intimp.2023.109996_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14712598.2018.1474197","article-title":"Serum thymosin alpha 1 levels in normal and pathological conditions","volume":"18","author":"Pica","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13613-020-00661-z","article-title":"Therapeutic strategies for critically ill patients with COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.intimp.2023.109996_b0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41420-020-0283-2","article-title":"Off-label therapy targeting pathogenic inflammation in COVID-19","volume":"6","author":"Romani","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.intimp.2023.109996_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106873","article-title":"Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study","volume":"88","author":"Wu","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"16","key":"10.1016\/j.intimp.2023.109996_b0060","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/cid\/ciaa630","article-title":"Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells","volume":"71","author":"Liu","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2023.109996_b0065","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2006-02-004762","article-title":"Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance","volume":"108","author":"Romani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109996_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107022","article-title":"Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy","volume":"90","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"sup1","key":"10.1016\/j.intimp.2023.109996_b0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14712598.2018.1481207","article-title":"The effect of thymosin alpha1 for prevention of infection in patients with severe acute pancreatitis","volume":"18","author":"Yang","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2023.109996_b0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/1568026621666210429083050","article-title":"The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area","volume":"21","author":"Meng","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.intimp.2023.109996_b0085","doi-asserted-by":"crossref","first-page":"e1009878","DOI":"10.1371\/journal.ppat.1009878","article-title":"Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection","volume":"17","author":"Severa","year":"2021","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.intimp.2023.109996_b0090","first-page":"397","article-title":"A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity","volume":"31","author":"Etna","year":"2014","journal-title":"ALTEX"},{"issue":"6508","key":"10.1016\/j.intimp.2023.109996_b0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109996_b0100","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fimmu.2020.01513","article-title":"The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses","volume":"11","author":"Soto","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109996_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5501\/wjv.v9.i5.67","article-title":"Thymosin alpha 1: A comprehensive review of the literature","volume":"9","author":"Dominari","year":"2020","journal-title":"World J Virol"},{"key":"10.1016\/j.intimp.2023.109996_b0110","article-title":"Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.109996_b0115","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1517\/14712598.2015.1019460","article-title":"Dual effect of Thymosin alpha 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists","volume":"15","author":"Giacomini","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.109996_b0120","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1517\/14712598.2015.1033393","article-title":"Historical review of thymosin alpha 1 in infectious diseases","volume":"15","author":"Camerini","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.109996_b0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1352458517695892","article-title":"Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients","volume":"24","author":"Giacomini","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.intimp.2023.109996_b0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.msard.2018.09.035","article-title":"Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application","volume":"27","author":"Severa","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.109996_b0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1196\/annals.1415.002","article-title":"Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance","volume":"1112","author":"Romani","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"13","key":"10.1016\/j.intimp.2023.109996_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137017","article-title":"Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators","volume":"22","author":"Ricci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2023.109996_b0145","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2023.109996_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030628","article-title":"Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14336\/AD.2020.0831","article-title":"Coronavirus Disease (COVID-19): A Perspective from Immunosenescence","volume":"12","author":"Genebat","year":"2021","journal-title":"Aging Dis."},{"issue":"7","key":"10.1016\/j.intimp.2023.109996_b0160","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/21645515.2020.1871295","article-title":"Immunotherapies and immunomodulatory approaches in clinical trials - a mini review","volume":"17","author":"Iqbal Yatoo","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2023.109996_b0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun. Ageing"},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/03007995.2020.1853508","article-title":"Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study","volume":"37","author":"Wang","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.intimp.2023.109996_b0175","article-title":"Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109996_b0180","doi-asserted-by":"crossref","first-page":"913","DOI":"10.5005\/jp-journals-10071-24298","article-title":"A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin alpha1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients","volume":"26","author":"Shetty","year":"2022","journal-title":"Indian J Crit Care Med"},{"issue":"5","key":"10.1016\/j.intimp.2023.109996_b0185","first-page":"497","article-title":"Thymosin alpha 1 for the adjuvant treatment of coronavirus disease 2019: a retrospective cohort study","volume":"34","author":"Wang","year":"2022","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.intimp.2023.109996_b0190","article-title":"Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.intimp.2023.109996_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107143","article-title":"The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study","volume":"90","author":"Sun","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.109996_b0200","article-title":"A Pilot Trial of Thymalfasin (Talpha1) to Treat Hospitalized Patients with Hypoxemia and Lymphocytopenia due to COVID-19 Infection","author":"Shehadeh","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2023.109996_b0205","article-title":"Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes","volume":"114","author":"Shang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.109996_b0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajem.2021.04.043","article-title":"Thymosin a1 use is not associated with reduced COVID-19 mortality","volume":"53","author":"Liu","year":"2022","journal-title":"Am. J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.109996_b0215","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2023.109996_b0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.humimm.2020.12.010","article-title":"Dynamic changes in monocytes subsets in COVID-19 patients","volume":"82","author":"Qin","year":"2021","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0225","doi-asserted-by":"crossref","first-page":"20254","DOI":"10.1038\/s41598-021-99705-y","article-title":"Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals","volume":"11","author":"Rajamanickam","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12865-022-00526-z","article-title":"Restoration of dendritic cell homeostasis and Type I\/Type III interferon levels in convalescent COVID-19 individuals","volume":"23","author":"Rajamanickam","year":"2022","journal-title":"BMC Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109996_b0235","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41423-021-00728-2","article-title":"Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection","volume":"18","author":"Perez-Gomez","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1590\/S0100-879X2011007500159","article-title":"Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro","volume":"45","author":"Yang","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0245","first-page":"p. ofaa588","article-title":"Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum","volume":"8","author":"Matteucci","year":"2021","journal-title":"Infect. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2023.109996_b0250","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","article-title":"Immune cell migration in inflammation: present and future therapeutic targets","volume":"6","author":"Luster","year":"2005","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2023.109996_b0255","doi-asserted-by":"crossref","first-page":"879885","DOI":"10.1093\/ajhp\/58.10.879","article-title":"Thymosin alpha-1","volume":"58","author":"Ancell","year":"2001","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0260","first-page":"51","article-title":"Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers","volume":"37","author":"Rost","year":"1999","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109996_b0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cei.12833","article-title":"Serum thymosin alpha 1 levels in patients with chronic inflammatory autoimmune diseases","volume":"186","author":"Pica","year":"2016","journal-title":"Clin. Exp. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692300317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692300317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:57:03Z","timestamp":1761587823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692300317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":53,"alternative-id":["S156757692300317X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109996","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel evidence of Thymosin \u03b11 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109996"}}